Published in World J Gastroenterol on August 21, 2014
Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol (2016) 0.78
Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology. World J Gastroenterol (2015) 0.78
Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.78
Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol (2016) 0.75
Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. HPB (Oxford) (2016) 0.75
Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. Int J Mol Sci (2016) 0.75
Glycosylation site occupancy in health, congenital disorder of glycosylation and fatty liver disease. Sci Rep (2016) 0.75
Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. Clin Pharmacol Ther (2016) 0.75
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol (2017) 0.75
Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep (2016) 0.75
Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway. Exp Ther Med (2015) 0.75
A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep (2017) 0.75
Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. Int J Mol Sci (2016) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Liver biopsy. N Engl J Med (2001) 9.91
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (2007) 5.53
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol (2008) 4.01
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (2008) 3.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther (2012) 3.35
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells (2004) 2.88
Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol (2004) 2.70
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology (2010) 2.58
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab (2006) 2.34
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med (2004) 2.29
Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology (2008) 2.26
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut (2010) 2.20
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology (2008) 1.93
Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology (1988) 1.91
Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol (2007) 1.90
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
MRI and ultrasound for hepatic fat quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr (2007) 1.83
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol (2005) 1.80
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis (2007) 1.79
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg (2011) 1.79
Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology (2010) 1.71
Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology (2008) 1.71
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut (2008) 1.63
Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2005) 1.63
Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci (2008) 1.63
Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology (2010) 1.60
Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 1.60
Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr (2005) 1.58
Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab (2008) 1.52
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Alteration of protein glycosylation in liver diseases. J Hepatol (2008) 1.47
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab (2004) 1.43
Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int (2006) 1.40
Heterogeneity of hemochromatosis in Italy. Gastroenterology (1998) 1.38
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology (2007) 1.37
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol (2008) 1.36
Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35
A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol (2010) 1.32
Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr (2006) 1.31
Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2005) 1.30
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology (2005) 1.29
Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut (2007) 1.29
Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol (2007) 1.28
Physical state of meal affects gastric emptying, cholecystokinin release and satiety. Br J Nutr (1998) 1.28
Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int (2005) 1.27
APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J (2011) 1.26
Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab (2006) 1.23
Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol (2008) 1.21
Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int (2006) 1.21
Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr (2005) 1.19
Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology (2003) 1.18
Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr (2010) 1.18
Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol (2007) 1.17
Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int (2010) 1.16
Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut (2006) 1.15
Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int (2005) 1.13
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr (2010) 1.13
The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med (2009) 1.12
Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut (2008) 1.11
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics (2009) 1.09
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol (2012) 1.07
Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Paediatr (2006) 1.06
A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol (2010) 1.05
Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol (2011) 1.04